ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 723

Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation

Robert Durcan1, Wei Fu2 and Michelle Petri3, 1Beaumont Hospital, Dublin, Ireland, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: oral, systemic lupus erythematosus (SLE) and ulcers

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Oral ulcers (OU) are a common manifestation of systemic lupus erythematosus (SLE). They are included in both classification criteria and disease activity indices. Despite this, there has been little done to further characterize them. This work was undertaken to evaluate the disease specific features associated with OU in SLE. We then sought to specifically evaluate a subgroup of individuals regarding the patient reported features of OU in SLE. 

Methods: The prevalence of OU in a large SLE cohort was examined and their relationship to the other SLICC criteria explored using logistic regression. Phase 2 involved the administration of a questionnaire outlining the characteristics, location, duration and number of OU.

Results: There were 2417 SLE patients in the initial analysis. The frequency of OU in the cohort was 51.6%. Male gender (OR=0.48, 95% CI =0.35, 0.66) and African-American race (OR=0.52, 95% CI = 0.33, 0.80) were negatively associated with oral ulcers. The relationship between OU and the other SLICC clinical and laboratory criteria, after adjusting for ethnicity, are as outlined in Table1. 

Oral ulcers were positively associated with cutaneous lupus, alopecia and arthritis. They were associated with pleurisy but not pericarditis. Oral ulcers were negatively associated with “seropositivity” (low complement, high anti-dsDNA) and renal lupus. 123 patients were surveyed (3 could give no details). 68 (56.6%) had as history of OU. Mean duration of OU was 7.43 days (range: 1 to 90). Regarding location, 22 (32.4%) described them on their tongue, 23 (33.8%) on the palate and 50 (73.5%) on their buccal mucosa. 34 (50%) described crops of OU. Addressing pain, 54 of the 68 patients provided information. 34 (63%) said that they only had painful episodes, 12 (22%) had only painless episodes, and 8 (15%) have both.

 

Table 1 Relationship between OU and the other SLE manifestations.

SLICC Criteria

History of OU (%)

No OU (%)

Odds ratio

95% CI

P value

(unadjusted)

P value

(adjusted for ethnicity)

Acute cutaneous lupus

Malar Rash

55.6

42.4

1.58

(1.34,1.86)

<.0001

<.0001

Bullous Lupus

1.1

0.4

2.61

(0.91,7.43)

0.0883

0.0731

Photosensitivity

60.7

43.3

1.84

(1.56,2.17)

<.0001

<.0001

Chronic cutaneous lupus

Discoid Lupus

20.4

18.4

1.38

(1.12,1.71)

0.2124

0.0027

Alopecia

60.9

49.2

2.11

(1.77,2.52)

<.0001

<.0001

Arthritis

74.2

69.3

1.32

(1.1,1.59)

0.0078

0.0024

Serositis

Pleurisy

46.9

39.6

1.39

(1.18,1.64)

0.0003

0.0001

Pericarditis

22.1

21.8

1.12

(0.92,1.36)

0.8705

0.2655

Renal

Proteinuria

37.8

50.7

0.68

(0.57,0.8)

<.0001

<.0001

Neurologic

Seizures

9.5

9.5

1.01

(0.77,1.34)

0.9906

0.9255

Acute Confusional State

5.0

3.2

1.60

(1.05,2.43)

0.0259

0.0297

Hemolytic Anemia

8.5

11.7

0.75

(0.57,0.99)

0.0120

0.0393

Leukopenia

46.5

45.4

1.16

(0.99,1.37)

0.6081

0.0718

Thrombocytopenia

19.2

21.6

0.89

(0.73,1.09)

0.1493

0.2493

ANA

96.2

96.9

0.88

(0.56,1.38)

0.3328

0.5775

Anti-dsDNA

58.2

65.2

0.77

(0.65,0.91)

0.0004

0.0022

Anti-Sm

19.0

22.0

1.01

(0.82,1.25)

0.0753

0.9244

Anti-phospholipid

LAC

25.7

27.1

0.88

(0.73,1.07)

0.4738

0.1977

Anticardiolipin

48.6

48.5

0.99

(0.84,1.16)

0.9683

0.8645

Anti-beta 2 gly

27.8

30.3

0.85

(0.67,1.07)

0.2859

0.1682

Low complement

C3

51.1

58.7

0.78

(0.66,0.92)

0.0002

0.0034

C4

45.7

49.4

0.88

(0.75,1.04)

0.0683

0.1274

Coombs

17.3

23.4

0.75

(0.60,0.94)

0.0008

0.0133

Conclusion: Mouth ulcers occur in 51% of SLE patients. They are negatively associated with “seropositivity” (meaning anti-dsDNA and low complement) and with renal lupus. Surprisingly, they are associated with pleurisy but not pericarditis. The majority occur on the buccal mucosa. In contradistinction to the ACR criteria, 63% of patients have painful episodes.


Disclosure: R. Durcan, None; W. Fu, None; M. Petri, None.

To cite this abstract in AMA style:

Durcan R, Fu W, Petri M. Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/oral-ulcers-in-systemic-lupus-erythematosus-characterization-and-clarification-of-an-important-clinical-manifestation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oral-ulcers-in-systemic-lupus-erythematosus-characterization-and-clarification-of-an-important-clinical-manifestation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology